Valieva had multiple substances in system, says US daily


Russian figure skater Kamila Valneva has tested positive for three different substances used to treat heart conditions, according to The New York Times. – EPA pic, February 16, 2022.

RUSSIAN figure skater Kamila Valieva had three different substances used to treat heart conditions in the sample that triggered the doping storm at the Beijing Olympics, The New York Times reported yesterday.

Valieva learnt during the Games she had tested positive last December for trimetazidine, a drug used to treat angina that also boosts endurance.

On Monday, the Court of Arbitration for Sport (CAS) ruled that she could carry on at the Olympics but that does not mean she has been cleared of doping and she could still face punishment at a later date.

The Times reported that her sample also contained the heart medications hypoxen and L-Carnitine, which are not on the World Anti-Doping Agency’s prohibited list.

It reported that the disclosures concerning the different substances were contained in a document submitted at Sunday’s Court of Arbitration for Sport hearing that ended with the controversial decision to allow Valieva to compete.

Senior IOC member Denis Oswald told reporters in Beijing yesterday that Valieva told the CAS hearing she tested positive because of “contamination” from her grandfather’s medicine.

Russian media reported that Valieva allegedly drank from the same glass as her grandfather, who takes trimetazidine for a heart condition.

The Times report said Valieva’s grandfather had provided a pre-recorded video message to a hearing with Russian anti-doping officials on February 9 in which he said he used trimetazidine to treat “attacks”.

The athlete’s grandfather showed a packet of the medication during the message.

Valieva’s mother told the same hearing that her daughter took the substance hypoxen due to heart “variations”, the Times report said.

She added that Valieva’s grandfather also accompanied the teenager to practice daily. – AFP, February 16, 2022.



Sign up or sign in here to comment.


Comments